Mark C. McKenna, Chairman, President & CEO at Prometheus Biosciences, Inc. (RXDX), sold 25,000 shares at $116.14 ($2.9M) on 2023-03-15, disclosed to the SEC on 2023-03-17.
Scheduled sale ($2.9M) by Chairman, President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RXDX | SELL | 2023-02-17 | $7.7M | — | Filing → |
| RXDX | SELL | 2023-01-19 | $3.0M | — | Filing → |
| BHC | SELL | 2019-08-21 | $470K | — | Filing → |